LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

Home・Stock List・Cara Therapeutics Inc

Cara Therapeutics Inc

Closed

Sector Healthcare

0.36

Buy Sell

Overview

Share price change

24h

Current

Min

0.35

Max

0.39

Key metrics
By Trading Economics
Income	-28M
Sales	-1.9M 3M
EPS	-0.59
Profit margin	-576.079
Employees	55
EBITDA	-29M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+170.27 upside

Dividends
By Dow Jones
Next Earnings	5 Aug 2024

Market Stats
By TradingEconomics
Market Cap	-2.3M 46M
Previous open	0.36
Previous close	0.36

News Sentiment

By Acuity

92%

347 / 369 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

0.3316 / 0.3784 Support & Resistance

Cara Therapeutics Inc Chart

Related News

25 Jul 2024, 20:16 UTC

Earnings

Norfolk Southern Grows 2Q Profit, Seeks to Leave Behind Derailment Tailwinds

25 Jul 2024, 22:57 UTC

Earnings

Minas Buenaventura 2Q Net $74.4M >BVN

25 Jul 2024, 22:10 UTC

Earnings

Berkshire Is Quickly Cutting Its Stake in Bank of America. More Sales Could Be Coming. -- Barrons.com

25 Jul 2024, 21:59 UTC

Market Talk

Earnings

Global Energy Roundup: Market Talk

25 Jul 2024, 21:59 UTC

Market Talk

Earnings

Norfolk Southern Lowers Operating Ratio in 2Q, Shares Jump -- Market Talk

25 Jul 2024, 21:51 UTC

Earnings

Update: Berkshire Is Quickly Cutting Its Stake in Bank of America. More Sales Could Be Coming. -- Barrons.com

25 Jul 2024, 21:32 UTC

Acquisitions, Mergers, Takeovers

Noble: Special Meeting of Diamond Stockholders to Vote on Transaction Is Currently Scheduled for Aug 27 >NE

25 Jul 2024, 21:32 UTC

Acquisitions, Mergers, Takeovers

Noble Corp and Diamond Offshore: Announce Expiration of Hart-Scott-Rodino Act Waiting Period and Provide Transaction Update

25 Jul 2024, 21:18 UTC

Earnings

A.J. Gallagher Earnings Show Insurance Brokers Are Anything but Humdrum -- Barrons.com

25 Jul 2024, 21:11 UTC

Peer Comparison

Price change

Cara Therapeutics Inc Forecast

Price Target

By TipRanks

170.27% upside

12 Months Forecast

Average 1 USD 170.27%

High 1 USD

Low 1 USD

Based on 5 Wall Street analysts offering 12 month price targets forCara Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Cara Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.3316 / 0.3784Support & Resistance

All events are bullish.

Recent bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

347 / 369 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

About Cara Therapeutics Inc

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The Company is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The Company is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates.